Physician profile
Vikas Passi
NPI 1710932769
$11,773.29
in general payments reported to CMS, 2019-2025
44 companies · $2,084 in 2025
The $2,084 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,597 · 2020: $395 · 2021: $1,665 · 2022: $2,039 · 2023: $1,903 · 2024: $2,090 · 2025: $2,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,976 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,975.57 |
| Education | $101.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,885.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,860.46 | 2019-2025 | Mounjaro, Jardiance, Amyvid |
| Abbvie INC. | $1,099.42 | 2021-2025 | |
| Amgen INC. | $989.80 | 2019-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $824.90 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $822.15 | 2019-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Astrazeneca Pharmaceuticals LP | $591.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $492.03 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $395.76 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.30 | 2019-2023 | Stiolto Respimat, Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $321.54 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $247.37 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $234.81 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $161.24 | 2022-2024 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $152.17 | 2019-2025 | Rexulti, Nuedexta |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Passi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.